{"id":"https://openalex.org/W2554340669","doi":"https://doi.org/10.1182/blood.v118.21.2814.2814","title":"Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)","display_name":"Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)","publication_year":2011,"publication_date":"2011-11-18","ids":{"openalex":"https://openalex.org/W2554340669","doi":"https://doi.org/10.1182/blood.v118.21.2814.2814","mag":"2554340669"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v118.21.2814.2814","doi":"https://doi.org/10.1182/blood.v118.21.2814.2814","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v118.21.2814.2814","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA,","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046051756","display_name":"Susanne Kloeker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Susanne Kloeker Rhoades","raw_affiliation_strings":["Lilly Oncology, Eli Lilly, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004676919","display_name":"Jennifer L K Giles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer L K Giles","raw_affiliation_strings":["Lilly Oncology, Eli Lilly, Indianapolis, IN,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly, Indianapolis, IN,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034695625","display_name":"Celine Pitou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Celine Pitou","raw_affiliation_strings":["Lilly Oncology, Eli Lilly, Erl Wood, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly, Erl Wood, United Kingdom,","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005741149","display_name":"Emma Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095227","display_name":"Eli Lilly (United Kingdom)","ror":"https://ror.org/00psab413","country_code":"GB","type":"company","lineage":["https://openalex.org/I168537998","https://openalex.org/I4210095227"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Emma Jones","raw_affiliation_strings":["Lilly Oncology, Eli Lilly, Erl Wood, United Kingdom,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly, Erl Wood, United Kingdom,","institution_ids":["https://openalex.org/I4210095227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009773917","display_name":"Richard A. Walgren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard A Walgren","raw_affiliation_strings":["Lilly Oncology, Eli Lilly and Company, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly and Company, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042381475","display_name":"Josef T. Prchal","orcid":"https://orcid.org/0000-0002-8019-2940","observed_orcids":["https://orcid.org/0000-0002-8019-2940"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josef T. Prchal","raw_affiliation_strings":["MPD-Research Consortium, Hematology Division, University of Utah School of Medicine, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MPD-Research Consortium, Hematology Division, University of Utah School of Medicine, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5004676919","https://openalex.org/A5005741149","https://openalex.org/A5034695625","https://openalex.org/A5046051756"],"corresponding_institution_ids":["https://openalex.org/I168537998","https://openalex.org/I4210095227"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":3.9767,"has_fulltext":false,"cited_by_count":35,"citation_normalized_percentile":{"value":0.93971364,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"118","issue":"21","first_page":"2814","last_page":"2814"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9539999961853027},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9980000257492065},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":1.0},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9629999995231628},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5950000286102295},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8640000224113464},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8230000138282776},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9330000281333923},{"id":"https://openalex.org/keywords/jak2-stat5-signaling","display_name":"JAK2/STAT5 signaling","score":0.6259999871253967},{"id":"https://openalex.org/keywords/symptom-burden","display_name":"symptom burden","score":0.3790000081062317}],"concepts":[{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.8566986322402954},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.8085556030273438},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.7853169441223145},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6925582885742188},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.654794454574585},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5707701444625854},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5151980519294739},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.4825820028781891},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38072142004966736},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.34103429317474365},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.33242321014404297},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3304382860660553},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.26421093940734863},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.19739189743995667}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v118.21.2814.2814","doi":"https://doi.org/10.1182/blood.v118.21.2814.2814","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v118.21.2814.2814","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W150400455","https://openalex.org/W2559563976","https://openalex.org/W2584660382","https://openalex.org/W4417007058","https://openalex.org/W2751027104","https://openalex.org/W2561728622","https://openalex.org/W2588005189","https://openalex.org/W2036153681","https://openalex.org/W2562725367","https://openalex.org/W2079645940"],"abstract_inverted_index":{"Abstract":[0,1,93],"2814":[2],"Background:":[3],"The":[4,117,189,204,357],"majority":[5],"of":[6,20,35,53,82,127,152,156,246,294,301,312,321,336,404,412,455,468,481,508,532,534,545,551,584,607,624,651,676,684],"primary":[7,118],"and":[8,12,68,86,111,125,129,154,170,173,235,255,268,279,303,318,331,345,350,394,420,523,539,562],"secondary":[9],"MF,":[10,109,144,234,441],"PV,":[11,110,231],"ET":[13,112,171],"neoplasms":[14],"are":[15,120,491],"characterized":[16],"by":[17,45,425,463,549],"gain-of-function":[18],"activation":[19],"JAK2":[21,27,42,48,55,76,83,142,618],"V617F/STAT5":[22,84],"signaling.":[23],"Given":[24],"that":[25,309],"wild-type":[26,54],"plays":[28],"a":[29,74,131,192,445,460,470,514,526,568,637,685],"pivotal":[30],"role":[31],"in":[32,56,69,108,139,265,334,410,432,472,479,500,517,529,559,570,616],"multiple":[33],"stages":[34],"hematopoiesis":[36],"it":[37],"is":[38,680],"desirable":[39],"to":[40,59,121,197,209,457,602,635,643,648,681],"treat":[41],"V617F-positive":[43,143],"cases":[44,335],"selectively":[46],"inhibiting":[47],"V617F":[49,619],"while":[50,555],"minimizing":[51],"inhibition":[52,81],"order":[57],"not":[58,575],"impede":[60],"normal":[61],"marrow":[62,474,663],"function.":[63],"In":[64,440],"murine":[65,617],"MPN":[66,520],"models":[67],"vitro":[70],"cell":[71,88],"based":[72],"assays,":[73],"novel":[75],"inhibitor,":[77],"LY2784544,":[78],"demonstrates":[79],"selective":[80],"signaling":[85],"mutant":[87,571],"proliferation":[89],"(Ma":[90],"et":[91],"al.":[92,186],"4087":[94],"ASH":[95],"2010).":[96],"These":[97],"results":[98,490,683],"provided":[99],"the":[100,103,123,159,177,199,247,299,482,494,504,518,530,604,608,627,629,661],"basis":[101],"for":[102,136,168,244,427,437,486,553,581],"LY2784544":[104,128,585,677],"Phase":[105],"I":[106],"trial":[107,655],"patients":[113,140,226,240,415,443,485,497,552],"(I3X-MC-JHTA,":[114],"NCT01134120).":[115],"Methods:":[116],"objectives":[119,149],"determine":[122],"safety":[124],"tolerability":[126],"define":[130,198],"recommended":[132],"oral":[133],"daily":[134,582],"dose":[135,202,612,639,652],"further":[137,649,659],"study":[138,190,205],"with":[141,289,348,450,599],"ET,":[145],"or":[146,453],"PV.":[147],"Secondary":[148],"include":[150,636],"determination":[151],"pharmacokinetics":[153],"evaluation":[155],"response":[157,161,166,424],"using":[158,176,298],"IWG-MRT":[160],"criteria,":[162],"European":[163],"Leukemia":[164],"Net":[165],"criteria":[167],"PV":[169,428],"(EULN),":[172],"symptom":[174,501],"burden":[175,502,573],"Myeloproliferative":[178],"Neoplasm":[179],"Symptom":[180],"Assessment":[181],"Form":[182],"(MPN-SAF)":[183],"(Scherber":[184],"et.":[185],"Blood":[187],"2011).":[188],"has":[191,574,632],"standard":[193],"3+3":[194],"dose-escalation":[195],"design":[196],"maximum":[200],"tolerated":[201],"(MTD).":[203],"was":[206,408,435,477,547,586],"recently":[207],"amended":[208,634],"allow":[210,622],"cohort":[211],"expansions":[212],"at":[213,343,353,405],"lower":[214,605,638],"than":[215],"MTD":[216,580],"doses":[217,597,625],"demonstrating":[218],"potential":[219],"clinical":[220,324,461],"merit.":[221],"Results:":[222],"To":[223,621],"date,":[224],"19":[225],"have":[227],"been":[228,576,633],"treated:":[229],"1":[230,232,243,310,349,391],"post-ET":[233],"17":[236,413],"MF":[237,419,484],"patients.":[238],"Four":[239],"discontinued":[241],"therapy,":[242,469],"each":[245,354],"following:":[248],"Adverse":[249],"Event,":[250],"progressive":[251],"disease,":[252],"investigator":[253],"decision,":[254],"subject's":[256],"decision.":[257],"Reported":[258],"drug-related":[259,361],"serious":[260],"adverse":[261],"events":[262],"were":[263,338,366],"seen":[264,409],"4":[266,378,449],"patients,":[267],"include:":[269],"creatinine":[270,332,383],"increase":[271],"(n=4":[272],"grade":[273,277,282,369,372,376,379,385,389,392,397,476],"2),":[274,386],"hyperuricemia":[275,395],"(2":[276,396],"4),":[278],"hyperkalemia":[280],"(1":[281],"1).":[283],"All":[284],"resolved":[285],"within":[286,503,626],"14":[287],"days":[288],"temporary":[290],"treatment":[291],"interruption.":[292],"Analysis":[293],"collected":[295],"laboratory":[296,313],"studies":[297],"definitions":[300],"Cairo":[302],"Bishop":[304],"(BJH":[305],"2004,":[306],"2010)":[307],"demonstrated":[308],"instance":[311],"tumor":[314,325,645],"lysis":[315,326],"syndrome":[316,327],"(LTLS)":[317],"3":[319,351,480],"instances":[320,352],"Grade":[322],"2":[323,506],"(CTLS)":[328],"occurred.":[329],"Hyperuricemia":[330],"increases":[333],"TLS":[337,600],"reported":[339,360,498,513,525,548],"as":[340,459,588],"dose-limiting":[341],"toxicities":[342],"240":[344],"200":[346],"mg":[347],"respective":[355],"dose.":[356],"most":[358],"frequently":[359],"AEs":[362],"across":[363],"all":[364],"grades":[365],"diarrhea":[367],"(3":[368,375,388],"2,":[370,377,390],"5":[371,466,483],"1),":[373,380,393],"nausea":[374],"transient":[381],"increased":[382],"(4":[384],"anemia":[387],"4).":[398],"A":[399,422,542],"palpable":[400],"spleen":[401,433],"length":[402],"reduction":[403,431,471,569],"least":[406],"35%":[407,556],"13":[411],"evaluable":[414],"(76%":[416],"including":[417,448],"16":[418],"1PV).":[421],"partial":[423],"EULN":[426],"involving":[429],"100%":[430],"size":[434],"observed":[436,478],">10":[438],"months.":[439],"7":[442],"had":[444,557],"\u226550%":[446,515,527],"reduction,":[447],"sufficient":[451],"stability":[452],"duration":[454],"follow-up":[456,488],"qualify":[458],"improvement":[462,516,528,546],"IWG-MRT.":[464],"After":[465],"cycles":[467,507],"bone":[473,560,662],"fibrosis":[475,664],"whom":[487],"biopsy":[489],"available.":[492],"Using":[493],"MPN-SAF":[495],"questionnaire,":[496],"improvements":[499,558],"first":[505],"therapy.":[509],"Fifty-nine":[510],"percent":[511],"(59%)":[512],"Key":[519],"Related":[521],"Symptoms,":[522],"47%":[524],"categories":[531],"Fatigue-Enjoyment":[533],"Life,":[535],"Fatigue-Walking":[536],"Ability,":[537],"itching,":[538],"early":[540],"satiety.":[541],"similar":[543],"level":[544],"65%":[550],"inactivity,":[554],"pain":[561],"night":[563],"sweats.":[564],"At":[565],"tested":[566],"doses,":[567],"allele":[572],"observed.":[577],"Conclusions:":[578],"An":[579],"dosing":[583,630],"identified":[587],"120":[589],"mg.":[590],"Based":[591],"on":[592],"PK":[593],"analysis,":[594],"exposure":[595],"from":[596],"associated":[598],"appear":[601],"overlap":[603],"boundary":[606],"predicted":[609],"biologically":[610],"efficacious":[611],"(BED)":[613],"range":[614],"established":[615],"models.":[620],"testing":[623,650],"BED,":[628],"regimen":[631],"lead-in":[640],"period,":[641],"intended":[642],"reduce":[644],"burden,":[646],"prior":[647],"escalation.":[653],"This":[654],"amendment":[656],"will":[657],"also":[658],"evaluate":[660],"response.":[665],"Disclosures:":[666],"Verstovsek:":[667],"Eli":[668],"Lilly:":[669,698,709,714,719,724,729],"Research":[670,689,693,696,699,702,705],"Funding.":[671,706],"Off":[672],"Label":[673],"Use:":[674],"Study":[675],"-":[678],"Purpose":[679],"present":[682],"study.":[686],"Mesa:NS":[687],"Pharma:":[688],"Funding;":[690,694,697,700,703],"Astra":[691],"Zeneca:":[692],"SBio:":[695],"Incyte:":[701],"Celgene:":[704],"Kloeker":[707],"Rhoades:Eli":[708],"Employment,":[710,715,720,725,730],"Equity":[711,716,721,726,731],"Ownership.":[712,717,722,727,732],"Giles:Eli":[713],"Pitou:Eli":[718],"Jones:Eli":[723],"Walgren:Eli":[728]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":11}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-11-30T00:00:00"}